Multiple Myeloma | Specialty

Treating Newly Diagnosed High-Risk Smoldering Myeloma

January 16th 2019

Identifying Between Smoldering and Active Myeloma

January 16th 2019

Dr. Cho on Targets for Immunotherapy in Multiple Myeloma

January 15th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses current and emerging targets for immunotherapy in the treatment of patients with multiple myeloma.

Dr. Martin on Selinexor in Penta-Refractory Patients With Myeloma

January 15th 2019

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

January 12th 2019

Peter Voorhees, MD, discusses the clinical potential of adding daratumumab to bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Dr. Voorhees Discusses Safety Run-in of Daratumumab in Myeloma

January 12th 2019

Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Pomalidomide Shows Benefit in Lenalidomide-Refractory Myeloma

January 11th 2019

David S. Siegel, MD, PhD, discusses a potentially practice-changing trial in multiple myeloma.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma

January 10th 2019

David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.

Dr. Madduri on the Standard of Care for Transplant Eligible Patients With Myeloma

January 8th 2019

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.

Dr. Rifkin on Split Dosing of Daratumumab in Myeloma

January 4th 2019

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

Dr. Parekh on the Mechanism of Action of Selinexor in Myeloma

January 4th 2019

Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.

Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma

January 3rd 2019

Deepu Madduri, MD, discusses the status of transplant for eligible patients and the developments that are being made with CAR T-cell therapy in multiple myeloma.

Classes of Immunotherapy Under Investigation in Multiple Myeloma

December 27th 2018

Hearn Jay Cho, MD, PhD, discusses classes of immunotherapy under investigation in multiple myeloma.

Dr. Jagannath on Cancer Proliferation in Multiple Myeloma

December 21st 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Relapsed/Refractory Myeloma Landscape Slated to Expand

December 20th 2018

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma

December 18th 2018

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Jagannath Discusses Building on the Biology of Multiple Myeloma

December 17th 2018

Sundar Jagannath, MD, provides insight into the biology of multiple myeloma.

Dr. Cho on the Knowledge Deficit in Multiple Myeloma

December 15th 2018

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.